Skin : Impact Factor & More
eISSN: 2574-1624
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Skin Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | National Society for Cutaneous Medicine |
| Language | English |
| Publication Time | 4 |
| Editorial Review Process | Editorial review,Blind peer review |
| General Details | |
| Language | English |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 4 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Skin ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Skin
Gamer’s Dermatitis: When Victory Comes with a Rash
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Eruptive Cutaneous Metastatic Leiomyosarcoma
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Safety of Intramuscular Triamcinolone Injections for Hidradenitis Suppurativa Flares: Findings from a Retrospective Cohort Study
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Once-daily Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Patients Aged 2–5 Years With Diverse Skin Types: Subgroup Analysis From the Phase 3 INTEGUMENT-PED Trial
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
The Emotional Impact of Pyoderma Gangrenosum (PG): Real-world Experience of the PG Patient Journey
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Gamer’s Dermatitis: When Victory Comes with a Rash
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Eruptive Cutaneous Metastatic Leiomyosarcoma
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Safety of Intramuscular Triamcinolone Injections for Hidradenitis Suppurativa Flares: Findings from a Retrospective Cohort Study
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
Once-daily Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Patients Aged 2–5 Years With Diverse Skin Types: Subgroup Analysis From the Phase 3 INTEGUMENT-PED Trial
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
The Emotional Impact of Pyoderma Gangrenosum (PG): Real-world Experience of the PG Patient Journey
- 10 Mar 2026
- SKIN The Journal of Cutaneous Medicine
FAQs on Skin
How many articles did Skin publish last year? 
Who is the publisher of Skin?
